Clik here to view.
AbbVie CSO Tom Hudson to retire, replaced by medical chief
A day after Pfizer disclosed the departure of its longtime chief scientific officer, AbbVie is doing the same, announcing that research chief Tom Hudson is retiring. Roopal Thakkar Replacing Hudson is...
View ArticleThermo Fisher closes $3.1B Olink acquisition after UK antitrust review is...
Life sciences giant Thermo Fisher on Wednesday closed its $3.1 billion deal for Olink, adding protein analysis to its drug discovery tools in a move that’s likely to boost the growing proteomics...
View ArticleCMS rolls out policy proposals on non-opioid drugs, radiopharmaceuticals —...
The Centers for Medicare & Medicaid Services on Wednesday outlined a series of proposed policy changes for next year that would change the way non-opioid drugs and certain radiopharmaceutical...
View ArticleNovo-partnered Aspect Biosystems gets $70M+ cash injection from Canadian...
Aspect Biosystems has received $72.75 million in funding from the governments of Canada and British Columbia to advance its pipeline of preclinical 3D-printed tissue candidates. The Vancouver-based...
View ArticleClik here to view.
Almost all patients quit weight loss shots within two years, analysis finds
Only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years, according to a new analysis by pharmacy benefit manager Prime Therapeutics. The findings could make...
View ArticleNovartis to shut down San Diego technical research and development facility
In an effort to “evolve” its global development organization, Novartis is set to exit a technical research and development site in San Diego, the Swiss pharma confirmed to Endpoints News. The “phased...
View ArticleFDA rejects Novo Nordisk’s once-weekly insulin, questions manufacturing and...
Novo Nordisk’s once-weekly insulin has been turned down by the FDA, and the Danish pharma likely won’t be refiling until next year. The FDA rejection comes after the EU, Canada, Australia, Japan and...
View ArticleIpsen takes on another ADC, this time from Foreseen Biotechnology
Ipsen is adding a second antibody-drug conjugate to its plate. The French drugmaker said Thursday that it has inked a global licensing agreement for a preclinical ADC developed by Foreseen...
View ArticleClik here to view.
Pfizer's once-daily oral GLP-1 drug passes first clinical tests
Pfizer is making a move on its obesity pipeline after multiple quarters of questions from investors and analysts. The New York pharma giant said Thursday it will move a once-daily, modified release...
View ArticleTen biotech executives who reaped the biggest M&A windfalls, netting $40M+...
While M&A is typically a boon to the shareholders of an acquired startup, it can also be quite lucrative for the executives selling their business. Many C-suite leaders have special agreements in...
View ArticleClik here to view.
Funding for biotech startups had its best quarter in two years — sort of
Privately held drug developers raised about $6.7 billion in the second quarter, marking the best three-month stretch since the beginning of 2022 and the tail end of the high-flying days of the...
View ArticleClik here to view.
JPM’s life sciences VC team is growing
JP Morgan Life Sciences Private Capital hired a leading biotech investor as it continues to build out its team after having disclosed two recent investments. Joseph Siletto Joseph Siletto, a former...
View ArticleFaron details clinical plans for MDS drug; Cara to seek 'strategic' options
Plus, news about CSL Vifor, Akebia and Pan Cancer T: Faron gets FDA go-ahead for streamlined registrational path: The company said the regulator “acknowledged the difficulties” of running a controlled...
View ArticleJ&J and Emergent settle Covid contract dispute; Siegfried names new CEO
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Johnson & Johnson will hand over $50 million to Emergent to...
View ArticleClik here to view.
Illumina competitor Element Biosciences raises $277M in Series D
Element Biosciences has raised an additional $277 million in private financing to support commercialization of its benchtop DNA sequencer and an instrument launch as the company takes on market leader...
View ArticleAbbVie's Humira is still on top, but biosimilars are chipping away at its...
The share of AbbVie’s brand-name version of Humira has dropped to 82% of the total market, 13% less than in March, according to a Samsung report published Thursday. The cracks in AbbVie’s...
View ArticleSenate unanimously passes bipartisan pharma patent bill
The Senate in a unanimous vote Thursday afternoon passed a bill that aims to tackle pharmaceutical patent abuses by limiting the number of patents that companies can assert on any one drug. The bill,...
View ArticleAbbVie asks Supreme Court to reconsider ruling on attorney-client communication
AbbVie is asking the Supreme Court to reconsider a lower court’s ruling that attorney records are fair game in a case involving testosterone med AndroGel. The petition issued Thursday argues that a...
View ArticleRoche's gene therapy biotech Spark is laying off employees, ending some...
Roche’s Spark Therapeutics is letting staffers go and has “discontinued” several early-stage programs, a spokesperson confirmed to Endpoints News. “In May, Spark informed employees in an all-employee...
View ArticleClik here to view.
Mikael Dolsten isn’t the only one moving on from Pfizer; Lilly names interim...
Mikael Dolsten → As we learned on Tuesday, Mikael Dolsten is set to leave — but another Pfizer leader is already gone: Eli Lilly’s radiopharma partner Aktis Oncology has welcomed Akos Czibere as CMO....
View Article